EMA Recommends Granting a Marketing Authorisation for Relacorilant By Ogkologos - October 2, 2026 8 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the treatment of adult patients with epithelial ovarian, Fallopian tube or primary peritoneal cancer Source RELATED ARTICLESMORE FROM AUTHOR Annual Multicancer Early Detection Test Not Associated with a Lower Incidence Rate of Stage III or IV Cancer After Three Screening Rounds and 12... European Parliament Report on Europe’s Beating Cancer Plan Strengthens Commitment to Rare Cancer Care Beginning Surveillance Colonoscopy After 5 Years from Removal of High-Risk Adenomas Non-inferior than at 3 Years in Terms of Cumulative CRC Incidence MOST POPULAR For Small Cell Lung Cancer, Immunotherapy Drug Finally Brings Improved Survival October 3, 2018 A real Eureka moment for translation February 10, 2023 How I’m Working to Erase the Stigma of Lung Cancer: A... November 22, 2023 Animal Shelters Are Honoring Healthcare Workers By Naming Shelter Dogs After... April 22, 2020 Load more HOT NEWS Teenage (…and young adult) kicks The Barriers to Care Faced by LGBTQ People With Cancer: An... Why it’s difficult to estimate the number of extra cancer deaths... ESMO Gynaecological Cancers Congress 2022, 17 – 18 June 2022 Valencia,...
